HomeGUTS • NASDAQ
add
Fractyl Health Inc
Previous close
$1.02
Day range
$0.99 - $1.09
Year range
$0.83 - $3.48
Market cap
72.24M USD
Avg Volume
1.16M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 26.08M | 13.37% |
Net income | -27.89M | -61.87% |
Net profit margin | — | — |
Earnings per share | -0.57 | -58.33% |
EBITDA | -25.81M | -13.23% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 22.29M | -78.24% |
Total assets | 62.01M | -57.66% |
Total liabilities | 80.22M | 5.99% |
Total equity | -18.21M | — |
Shares outstanding | 50.29M | — |
Price to book | -2.83 | — |
Return on assets | -89.90% | — |
Return on capital | -117.15% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | -27.89M | -61.87% |
Cash from operations | -21.20M | -13.14% |
Cash from investing | -98.00K | 62.31% |
Cash from financing | 1.48M | 29,700.00% |
Net change in cash | -19.82M | -4.29% |
Free cash flow | -10.81M | 10.00% |
About
Fractyl Health is a Burlington, Massachusetts-based healthcare company focused on metabolic diseases like obesity and type 2 diabetes. The company developed Revita, an outpatient endoscopic procedure to modify duodenal dysfunction, and Rejuva, a gene therapy platform in preclinical development to enable the pancreas to produce glucagon-like peptide-1. Wikipedia
Founded
2010
Headquarters
Website
Employees
103
